Skip to main content
OpenTrials
Completed

NCT Number: NCT05926830

Extracorporeal Flow Abolition in Relation With Primary Insufficiency of Great Saphenous Veins (GSV) Using High Intensity Focused Ultrasound (HIFU) Generated by Sonovein: A Multi Center Prospective Pivotal Study

This is a multi-center series assessment with a planned accrual of 70 patients with diagnosed symptomatic primary GSV insufficiency. Patients will be consented at a Pre-Study Visit and evaluated for eligibility and for baseline characteristics of the disease. Patients will receive treatment with Sonovein for the targeted segments of GSV. At follow-up visits at 7 days (1 to 10 days), 3 months (+/- 20 days), 6 months (+/- 25 days), and 12 months (+/- 30 days) changes in veins and flow characteristics will be evaluated by ultrasound, and patient well-being, including pain which will be evaluated by patient-reported VAS evaluations. Continued follow-up for a total of 12 months will be completed prior to subject study exit. Adverse events (AE) will be assessed at every study visit following HIFU treatment.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Venous Insufficiency Cardiovascular Diseases Varicose Veins Vascular Diseases

Age range

22 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Praxis für Phlebologie, Melk, Austria

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Candidate for venous procedure with primary GSV insufficiency involving reflux in the segment to be treated
  • CEAP-clinical classification ≥ 2
  • Physical condition allowing ambulation after the procedure.
  • Agree to comply with the Clinical investigation plan and follow-up schedule of the study
  • Targeted tissue reachable for treatment with the device.
  • Age over 22 years at the time of enrollment.
  • No acute venous thrombosis.
  • No complete or near complete deep vein post-thrombotic disease.
  • Patient has signed and understood the written informed consent.

Exclusion criteria

  • Patient is pregnant
  • Known allergic reaction to anesthetics to be used.
  • Legally incapacitated or imprisoned patients
  • Patient's vein target not clearly visible on the ultrasound images (in B mode) at the inclusion visit
  • Patient participating in another clinical trial involving an investigational drug or device.
  • Ankle-brachial index <7 (ABI)
  • Undergoing active anticoagulant therapy within the last 6 months
  • Diameter of the treated anatomical segment below ≤ 2mm & above > 20mm
  • Patients where HIFU cannot be delivered to tissues where macro calcifications induce a significant shadow in the ultrasonic image
  • Patients where EPack must be put in contact with an ulcer
  • Patients with significant thick scars on the skin over the segment to be treated
  • Security distance respected in regards of :
  • nerves & bones
  • the surrounding vessels
  • Patient who may not be considered as good candidates for treatment by the investigator outside the explicit exclusion criteria above listed

Treatment and study plan

Sonovein Treatment

Device

The Sonovein System provides High Intensity Focused Ultrasound (HIFU) ablation of soft tissue. The energy is delivered via an extra-corporeal treatment probe, which includes an imaging system. The high-energy ultrasound waves propagate through the skin and are focused on a portion of the target tissue, generating intense heat and causing local cell apoptosis and progressive tissue volume reduction over the following months in the tissue. The process is then repeated in a stepwise fashion.

Primary outcomes

  1. Vein Occlusion Rate

    Time frame: 12 months

    Percentage of limbs with occlusion of the treated vein (as measured by Duplex ultrasound)

Secondary outcomes

  1. Complications

    Time frame: 12 months

    Number of limbs presenting complications and side effects resulting from the GSV intervention

  2. Reflux-free Rate

    Time frame: 12 months

    Percentage of limbs without reflux in the treated vein (as measured by Duplex ultrasound)

  3. Venous Clinical Severity Score (VCSS)

    Time frame: 12 months

    Assessment of venous disease (Scale 0-30: MIN=0 (least severe); MAX=30 (most severe))

  4. Clinical-Etiology-Anatomy-Pathophysiology (CEAP)

    Time frame: 12 months

    Clinical signs and symptoms of lower limb venous disease (Scale C0-C6: MIN: C0=no visible or palpable signs of venous disease; MAX: C6=active venous ulcer)

Sponsors and collaborators

Lead sponsor

Theraclion

Industry

Registry information

Official study title

Extracorporeal Flow Abolition in Relation With Primary Insufficiency of Great Saphenous Veins (GSV) Using High Intensity Focused Ultrasound (HIFU) Generated by Sonovein: A Multi Center Prospective Pivotal Study (VEINRESET)

Acronym: VEINRESET

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Jul 3, 2023
Registry last updated
Jun 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.